Prazosin Alcohol Dependence IVR Study

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
University of Washington
ClinicalTrials.gov Identifier:
NCT00167687
First received: September 9, 2005
Last updated: February 13, 2008
Last verified: February 2008
  Purpose

This double-blind placebo controlled pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduced alcohol consumption and alcohol craving in alcohol dependent individuals without Post Traumatic Stress Disorder (PTSD). The intervention period is six weeks.


Condition Intervention Phase
Alcoholism
Drug: prazosin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo-Controlled Trial of Prazosin for the Treatment of Alcohol Dependence

Resource links provided by NLM:


Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Number of days drinking during the six week intervention [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Number of drinks per drinking day consumed [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Daily craving intensity over the six week intervention [ Time Frame: six weeks ] [ Designated as safety issue: No ]

Enrollment: 23
Study Start Date: September 2005
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 2 Drug: prazosin

Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:

Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg


Detailed Description:

The objective of the project is to determine whether prazosin, an alpha-1 adrenergic receptor antagonist, decreases alcohol consumption and/or the subjective experience of alcohol craving in individuals without post-traumatic stress disorder (PTSD) who are seeking treatment for alcohol dependence.

The study hypotheses are: (1) Subjects treated with prazosin will report fewer drinking days and fewer drinks per drinking day than subjects treated with placebo, (2) subjects treated with prazosin will report decreased craving for alcohol as compared to subjects in the placebo condition, and (3) prazosin will be well-tolerated at the proposed dosage by subjects in the prazosin condition compared to subjects in the placebo condition.

This project is a double-blind, randomized, placebo-controlled trial of prazosin in subjects who are dependent on alcohol and have used alcohol within the last 30 days prior to randomization. The treatment phase will last 6 weeks and will include 40 subjects; 20 randomized to each experimental condition (prazosin and placebo). Participants in both the groups will be provided the same behavioral treatment for alcohol dependence throughout the course of the study. Participants in both groups will also use daily Interactive Voice Response (IVR) symptom monitoring technology to track daily fluctuations in alcohol use and craving, as well as medication compliance.

The study will be conducted at the Addiction Treatment Center (ATC) at VAPSHCS, Seattle division.

Participants will include 40 alcohol-dependent adults presenting for chemical dependency treatment at the VA Puget Sound Health Care System (VAPSHCS) Addiction Treatment Center as well as subjects recruited from the general public via advertisements in local weekly newspapers.

Study Procedures: Once potential study participants have undergone an initial screen to insure basic eligibility they will provide informed consent and will undergo a 2-hour baseline assessment that will include completing a diagnostic interview, paper-and-pencil packet of measures, and providing urine and blood specimens. After completion of these assessments, a final determination will be made within three business days as to whether the potential participant meets inclusion but not exclusion criteria. Eligible participants will then be randomized to one of the two treatment groups. The participants will be prompted three times each day by text messaging pages reminding them to take their study medications.

The behavioral treatment to be used in this study is the Medication Management protocol adapted from the procedure used in Project COMBINE. A clinical rescue strategy will be in place such that any participants who evidence severe clinical deterioration including consuming more than 140 standard equivalent drinks in any 7 day period will be removed from the protocol and offered inpatient treatment at VA PSHCS.

During the first two weeks of the study, participants will have twice-weekly orthostatic vital sign and adverse events monitoring by the study nurse or physician, then weekly thereafter. All serious or unexpected adverse events will be reported to the FDA and UW Human Subjects Committee in accordance with requirements. When participants have completed their medication treatment at 6 weeks post-randomization, they will repeat all the baseline measures and laboratory tests (urine and blood samples will be requested) except for the PCL and the California Verbal Learning Test.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 18 years of age or older
  • current DSM-IV diagnosis of alcohol dependence with some use in last 30 days
  • capacity to provide informed consent
  • no planned absences during six week active treatment period that would prevent weekly check-in wiht the study psychiatrist
  • English fluency

Exclusion Criteria:

  • Score 50 or greater on the PTSD Check List which suggests a current diagnosis of PTSD
  • Psychiatric disorder requiring any medication other than anti-depressants
  • Current diagnosis of opiate dependence or abuse, chronic treatment with any opiate-containing medications during the previous month, or urine positive for opioids
  • Significant acute or chronic medical illness, including unstable angina, recent myocardial infarction, history of congestive heart failure, preexisting hypotension (systolic lower than 110) or orthostatic hypotension (systolic drop greater than 20mmHg after two minutes standing or any drop with dizziness), insulin-dependent diabetes mellitus; chronic renal or hepatic failure, pancreatitis, gout, Meniere's disease, benign positional vertigo, narcolepsy
  • Concomitant use of trazodone, tadalafil or verdenafil
  • History of prazosin-sensitivity
  • Women who are pregnant, nursing infant(s), or of childbearing potential and not using a contraceptive method judged by the investigator to be effective
  • Signs or symptoms of alcohol withdrawal at the time of randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167687

Locations
United States, Washington
VA Puget Sound Health Care System
Seattle, Washington, United States, 98108
Sponsors and Collaborators
University of Washington
Investigators
Principal Investigator: Tracy Simpson, PhD VA Puget Sound Health Care System
Principal Investigator: Andrew Saxon, MD VA Puget Sound Health Care System
Principal Investigator: Charles Meredith, MD VA Puget Sound Health Care System
  More Information

Additional Information:
No publications provided

Responsible Party: Tracy Simpson, Ph.D., Seattle VA Medical Center
ClinicalTrials.gov Identifier: NCT00167687     History of Changes
Other Study ID Numbers: 05-5895-V 02
Study First Received: September 9, 2005
Last Updated: February 13, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by University of Washington:
Alcoholism
Randomized Controlled Trial

Additional relevant MeSH terms:
Alcoholism
Alcohol-Related Disorders
Substance-Related Disorders
Mental Disorders
Prazosin
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 24, 2014